The US cancer survivor population is rapidly growing. Cancer survivors are frequently excluded from cancer clinical trials and observational research.
T he number of US cancer survivors is rapidly growing, largely driven by the aging population, expanding cancer screening efforts, and improvements in cancer treatment. Over the past 30 years, the cancer survivor population increased 4-fold to 15.5 million in 2016 and is expected to reach 26.1 million by 2040. 1 Almost half of all survivors have lived 10 years after their initial diagnosis, and two-thirds have survived beyond 5 years. 2 Survivors have complex health needs, 3 including surveillance for recurrence, monitoring treatmentrelated toxic effects, and managing emerging diagnoses, such as chronic conditions 4 or new primary cancers.
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Cancer survivors are frequently excluded from cancer clinical trials. More than 80% of National Cancer Instituteaffiliated lung cancer trials exclude patients with a prior cancer. 6 Such restrictive eligibility criteria may exclude as many as 25% of patients newly diagnosed with lung cancer from participating trials. 7 Although considerable scientific progress 5 has been made understanding risk of developing a future primary cancer among specific groups of cancer survivors, this earlier work does not address how many patients diagnosed with incident cancer have survived a prior cancer. Understanding prevalence of prior cancer among patients with different types of incident cancer has important implications for both treatment and research.
Methods
We report prevalence of prior cancer among individuals newly diagnosed with cancer from January 2009 to December 2013 using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program of cancer registries. We linked observations across SEER 9 registries (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San FranciscoOakland, Seattle-Puget Sound, and Utah, all from 1975-2013) to estimate prevalence of prior cancer by incident cancer type and age (<65 years vs ≥65 years). Prevalence of prior cancer was derived from SEER sequence numbers, which represent the order of all primary reportable tumors (ie, not metastatic or recurrent tumors) diagnosed in a lifetime. Sequence number "00" indicates an individual has only 1 primary cancer. For persons with multiple primaries, the sequence number for the first cancer is "01," "02" for the second, and so forth. With few exceptions, including ovarian and prostate cancers, tumors from different anatomic sites, of different histology, or from separate organs of a pair are considered independent primaries.
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The University of Texas Southwestern institutional review board approved this study. We categorized incident cancers as a: (1) first or only primary; (2) second order or higher primary in the same cancer site (eg, 2 melanomas diagnosed at least 1 year apart); or (3) second order or higher primary in a different cancer site. The eAppendix in the Supplement lists tumors classified as belonging to the same or different site. SEER collects the number but not site of cancers diagnosed outside geographically defined registry areas; therefore, some (range, 1.0%-14.3%) cases are categorized as having a prior cancer of an unknown site (data not shown).
For persons with more than 1 cancer diagnosed in the same year (n = 23 150 [3.1% of total]), we were unable to determine the order of diagnoses within that year; therefore, we randomly selected 1 cancer for analysis. The majority of persons diagnosed with more than 1 cancer in the same year (n = 17 420 [75.2% of those with ≥1 cancer in same year and 2.4% of total]) were diagnosed with 2 cancers of the same site (eg, right and left breast cancer).
Results
There were 765 843 incident cancers diagnosed among 740 990 persons from January 2009 to December 2013, of which 141 021 (18.4%) represented a second order or higher primary cancer. The Table shows the proportion of incident cancers diagnosed as the first or only primary or a second order or higher primary of the same or different site. Prevalence of prior cancer differed by age: 11.0% among ages 20 to 64 years and 25.2% among ages 65 years or older (Table) . Prevalence also differed by incident cancer type. Among persons age 20 to 64 years, prior cancer was most prevalent among incident myeloid and monocytic leukemia (24.8%); anus, anal canal and rectum (18.2%); cervix and other female genital organs (eg, vagina, vulva; 15.0%); and lung and other respiratory (14.6%) cancers. Prior cancers in this younger age group generally occurred in a different cancer site, although second order breast, cervical, and other female genital, male genital, and testicular cancers were more often in the same site. For patients 65 years and older, incident cancers with highest prevalence of prior cancer were melanoma (36.9%); myeloid and monocytic leukemia (36.9%); bone and joints (34.0%); and urinary bladder and other urinary organs (32.5%). With the exception of breast cancer melanoma, most prior cancers among the older age group occurred in a different site.
Discussion

Implications for Cancer Care Delivery
One-quarter of older adults (≥65 years) and more than 10% of younger adults newly diagnosed with cancer have a history of
Key Points
Question How many patients diagnosed with incident cancer are cancer survivors?
Findings In an analysis of 740 990 persons in the Surveillance, Epidemiology, and End Results program newly diagnosed with cancer, approximately 25% of older adults (Ն65 years) and 11% of younger adults had a history of prior cancer. Prevalence of prior cancer ranged from 4% to 37% according to age and incident cancer type, with most prior cancers diagnosed in a different cancer site.
Meaning As the population of cancer survivors continues to grow, understanding the nature and impact of a prior cancer is critical to improving clinical trial accrual, generalizability of results from trials and observational studies, disease outcomes, and patient experience. Many cancer clinical trials exclude patients with a prior cancer, a practice that may exclude a substantial proportion of otherwise eligible patients. Excluding patients with a prior cancer likely arises from a long-held belief that a prior cancer diagnosis may interfere with study conduct and/or outcomes. However, this restrictive criterion limits generalizability and trial-generated knowledge to patients with a first or only primary-a slight majority of patients with certain cancer types. This is particularly concerning for older adults with uncommon cancers, where trial accrual is critical, standard therapies may be suboptimal, and prior cancer is prevalent.
Determining the impact of prior cancer exclusion criteria on trial accrual requires disease-specific and protocolspecific details, including stage and timing of prior cancer diagnoses. 9 In lung cancer, most trials use a 5-year exclusion window, 6 prior cancers generally occur within that window, and having a prior cancer does not adversely impact survival.
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Consequently, including patients with a prior cancer in lung cancer trials could substantially improve accrual without affecting study outcomes. The sizable number of cancers newly diagnosed among cancer survivors highlights the importance of addressing similar questions for other cancer types.
Patients with prior cancer are also frequently excluded from observational research, including treatment and outcome studies using SEER-Medicare, 12 Patterns of Care, 13 Cancer Care Outcomes Research and Surveillance Consortium, 14 and Veterans Health Administration 15 data. Because observational studies often provide real-world data to complement clinical trials, reconsidering the rationale of this eligibility criterion is important to advancing evidence-based practice.
Limitations
We could not determine order of multiple cancers diagnosed in the same year because only year of diagnosis is available in SEER data (ie, not month or day). Prior cancers diagnosed outside of registry geographic areas are reflected in sequence number only, and there is no corresponding information on the prior cancer characteristics, including site. However, these limitations pertained to fewer than 5% of the total cancer cases diagnosed in the study period and are unlikely to impact our conclusions.
Conclusions
As the cancer survivor population continues to grow, understanding the nature and impact of a prior cancer is critical to improving trial accrual, generalizability of results from trials and observational studies, disease outcomes, and patient experience.
Invited Commentary
Incident Cancer in Cancer SurvivorsWhen Cancer Lurks in the Background Nancy E. Davidson, MD
Thanks to improvements in public health and more effective treatments for infectious diseases and cardiovascular disease, life expectancy in the United States has measurably improved. With increasing age comes an increase in cancer incidence. Over the past 4 decades improvements in cancer screening and treatment mean that about two-thirds of individuals in the United States diagnosed with cancer today will live at least 5 years.
1 Thus, the need for evidence-based measures to optimize medical care for cancer survivors has emerged. In this issue of JAMA Oncology, Murphy et al 2 used the population-based Surveillance, Epidemiology, and End Results (SEER) program of cancer registries to address a seemingly simple question about the prevalence of a prior cancer diagnosis among individuals who are newly diagnosed with cancer. Data describing 740 990 patients who were newly diagnosed with cancer from 2009 to 2013 were reviewed to categorize 765 843 cancers into first cancers, second or higherorder primary cancers in the same site, and second or higherorder primary cancers in a different anatomic site. The results are startling: 25% of patients 65 years or older and 11% of patients ages 20 to 64 years carried a previous diagnosis of cancer. The majority of the cancers were diagnosed in a different site, and the incidence ranged from 4% to 37% depending on the patient age and incident cancer type.
The strengths of this analysis include the use of a wellestablished and large population-based data set that includes patients from across the United States. The decision to focus on cancers diagnosed from 2009 to 2013 means that the findings reflect the current landscape of risk factors for cancer, as well as contemporary medical practices in cancer screening, diagnosis, and treatment in the United States. Efforts to differentiate new cancers from recurrent or metastatic cancers in SEER are robust, reducing the possibility for confusing a new cancer diagnosis with a diagnosis of metastatic disease. A limitation is that these findings are not easy to extrapolate outside the United States because they are dependent on our constellation of risk factors (eg, prevalence of tobacco use) and our unique approach to medical practice.
So how can these data help us to improve care for the cancer survivor? First, and foremost, they reinforce our common knowledge that diagnosis of a first cancer is frequently associated with diagnosis of a second cancer because of shared underlying risk factors like tobacco use, obesity, or human papillomavirus exposure. In addition, treatment for a first cancer may predispose to the development of a second cancer as is seen with chemotherapy or radiotherapy-induced leukemia or tamoxifen-related uterine cancer. Thus, a first cancer affirms the need to develop and apply evidence-based prevention and screening strategies for survivors of cancer because they are a particularly highrisk population. These findings also confirm that individuals with a first cancer are especially well suited to participate in research studies to identify biomarkers of risk for subsequent cancers and prevention strategies, areas where we know far less than we wish.
Second, this analysis reminds us of the importance of taking both a nuanced and holistic approach to health care and clinical investigation. For example, for women 65 years and older, Murphy et al 2 show that 75% of breast cancers were first or only primaries whereas 21% of breast cancers were second order or higher primaries in their analysis. The women in the latter group are often excluded from participation in breast cancer trials though they account for a large number of breast cancers. Yet another analysis using SEER-Medicare data showed that women 67 to 79 years of age with a diagnosis of ductal carcinoma in situ or stage I breast cancer had a better survival than matched controls without a diagnosis of breast cancer. Furthermore, in these women, the most common cause of death was cardiovascular disease followed by non-breast cancers; breast cancer ranked as only the third most common cause of death in these women. 3 Thus, one could argue that these women, once treated for their primary breast cancer, would be best served by careful attention to their general health and the opportunity to participate in clinical trials for cancer treatment or other serious medical conditions if they arise. Finally, these findings should spur us to revisit our longaccepted policies of excluding many otherwise well patients with a history of previous early-stage invasive cancer from participation in cancer treatment trials. In particular these restrictions may greatly limit participation of older patients, the very population where cancer is most commonly diagnosed and where we are most in need of strong evidence to guide treatment. 4 This will require not only a consensus among trialists but also agreement by regulatory agencies 
